|
1) Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989; 321: 129-35
|
|
|
|
2) Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet. 2001; 357: 89-95
|
|
|
|
|
3) The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet. 1998: 351: 233-41
|
|
|
|
|
|
4) PPP (Primary Prevention Project) Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Diabetes Care. 2003; 26: 3264-72
|
|
|
|
|
|
5) Ridker PM, Cook NR, Lee IM, et al. Low-Dose Aspirin and Primary Prevention in Women. N Engl J Med. 2005; 352: 1293-304
|
|
|
|
|
|
6) Chew EY, Klein ML, Murphy RP, et al. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Arch Ophthalmol. 1995; 113: 52-5
|
|
|
|
|
|
7) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA. 1992; 268: 1292-300
|
|
|
|
|
|
8) Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16: 434-44
|
|
|
|
|
|
9) Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229-34
|
|
|
|
|
|
10) Belch J, MacCuish A, Campbell I, et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337: a1840
|
|
|
|
|
|
11) Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008; 300: 2134-41
|
|
|
|
|
|
12) Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373: 1849-60
|
|
|
|
|
|
13) A study of cardiovascular events in diabetes (ASCEND) study. 2008; http//www.ctsu.ox.ac.uk.ascend/ (accessed April 23, 2009)
|
|
|
|
|
|
14) Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229-34
|
|
|
|
|
|
15) ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988; 2: 349-60
|
|
|
|
|
|
16) Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994; 308: 81-106
|
|
|
|
|
|
17) Yasue H, Ogawa H, Tanaka H, et al; on behalf of the Japanese Antiplatelets Myocardial Infarction Study (JAMIS) investigators. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Am J Cardiol. 1999; 83: 1308-13
|
|
|
|
|
|
18) Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997; 96: 2751-3
|
|
|
|
|
|
19) Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). Circulation. 2004; 44: E1-E211
|
|
|
|
|
|
20) Shahar E, Folsom AR, Romm FJ, et al. Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 1996; 131: 915-22
|
|
|
|
|
|
21) Stafford RS. Aspirin use is low among United States outpatients with coronary artery disease. Circulation. 2000; 101: 1097-101
|
|
|
|
|